AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in this application:

Claim 1 (original): Use of methylphenidate and at least one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof, in the preparation of a medicament for the treatment of ADHD in a mammal, especially a human 5 being.

Claim 2 (original): Use as claimed in claim 1 wherein the melatonin or melatonin analogue is employed in an amount of from 0.005 to 1.00 mg/kg in treating ADHD.

Claim 3 (currently amended): Use as claimed in ~~any one of the preceding claims~~ claim1, wherein the medicament is formulated as a controlled release preparation.

Claim 4 (currently amended): Use as claimed in ~~any one of the preceding claims~~ claim 1, wherein the medicament is formulated as a solid oral formulation.

Claim 5 (currently amended): Use as claimed in ~~any one of the preceding claims~~ claim 1, wherein the medicament additionally contains one or more substances selected from the group of stimulants, hormones, analogues of such hormones, phyto-hormones, analogues of such phytohormones, and anti-oxidants.

Claim 6 (original): A method of preventing or treating ADHD disorder in a mammal, in particular a human, which comprises administering to said mammal a therapeutically effective amount of methylphenidate and one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof.

Claim 7 (original): A method as claimed in claim 6, wherein methyl phenidate and melatonin are applied simultaneously.

Claim 8 (original): A method as claimed in claim 6, wherein methyl phenidate and melatonin 30 are applied subsequently.

Claim 9 (original): A method as claimed in claim 8, wherein melatonin is administered following the administration of methyl phenidate.

Claim 10 (original): A pharmaceutical composition comprising, as active ingredients, methylphenidate and at least one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof, in conjunction with a pharmaceutically acceptable carrier.

Claim 11 (original): A pharmaceutical composition according to claim 10 comprising, as active ingredients, methylphenidate and melatonin, in conjunction with a pharmaceutically acceptable carrier.

Claim12 (original): Use of methylphenidate and at least one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof as claimed in claim 1, wherein methylphenidate and at least one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof are comprised in separate forms of administration.